Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

With a market capitalization approaching the $1 trillion mark, Eli Lilly is engaged in a close competitive race with Novo Nordisk for dominance in the obesity treatment sector. Market researchers ...

Pharmacy benefit managers (PBMs) significantly impact GTN revenue through rebates, but patient access issues persist due to ...

I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight, with ...

Neurocrine Biosciences, Inc. ( NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs December 16, 2025 12:00 PM EST ...